Medicare and erythropoietin

New England Journal of Medicine

Volumn 356, Issue 1, 2007, Pages 4-6

  Steinbrook, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; COST CONTROL; DIALYSIS; DRUG COST; DRUG MARKETING; DRUG MONITORING; HEALTH CARE COST; HEALTH CARE POLICY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MEDICARE; PATIENT SAFETY; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY;

EID: 33846032712     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp068296     Document Type: Article

References (5)

1. Report to the Chairman, Committee on Ways and Means, House of Representatives. End-stage renal disease: bundling of Medicare's payment for drugs with payment for all ESRD services would promote efficiency and clinical flexibility. Washington, DC: Government Accountability Office, November 2006. (GAO-07-77.) (Accessed December 12, 2006, at http://www.gao.gov/cgi-bin/getrpt? GAO-07-77.)
2. Steinbrook R. Haemoglobin concentrations in chronic kidney disease. Lancet. Published online November 17, 2006 (DOI: 10.1016-S0140-6736(06)69707-9).
3. USRDS 2006 annual data report: atlas of end-stage renal disease in the United States. Minneapolis: U.S. Renal Data System, 2006. (Accessed December 12, 2006 at http://www.usrds.org/adr.htm.)
4. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
5. FDA Public Health Advisory. Epoetin alfa (marketed as Procrit, Epogen); darbepoetin alfa (marketed as Aranesp). Rockville, MD: Food and Drug Administration, November 16, 2006. (Accessed December 12, 2006, at http://www.fda.gov/cder/drug/advisory/RHE.htm.)